Top Markets
Coin of the day
Miravant Medical Technologies Inc. Miravant Medical Technologies Inc.

Miravant Medical Technologies Inc.

MRVT
Rang in aandelen #42699
Miravant Medical Technologies Inc. operates as a specialized firm dedicated to... Miravant Medical Technologies Inc. operates as a specialized firm dedicated to pharmaceutical research and development. A cornerstone of its work involves PhotoPoint, an innovative photodynamic therapy designed to eradicate cancerous cells when exposed to light. Furthermore, the company manufactures the essential light-generating and light-delivery devices required for this treatment. Miravant's product pipeline includes several therapeutic agents: PHOTREX, which is aimed at treating wet age-related macular degeneration (AMD); MV9411, a photoreactive compound developed for managing plaque psoriasis; MV0633, which targets conditions like atherosclerosis, vulnerable atherosclerotic plaque, and restenosis; MV2101, designed to address vascular access graft disease in hemodialysis patients; and MV6401, a treatment under development for solid tumors. The organization, originally established as PDT, Inc., officially adopted its current name, Miravant Medical Technologies Inc., in September of 1997. Founded in 1989, it maintains its corporate headquarters in Santa Barbara, California.
Aandeelprijs
$0.00001
Laatst gesynchroniseerd: 2025-06-16
Marktkapitalisatie
$352.62
Verandering (1 dag)
-99.67%
Verandering (1 jaar)
0.00%
Land
US
Handel Miravant Medical Technologies Inc. (MRVT)

Categorie

P/B-ratio voor Miravant Medical Technologies Inc. (MRVT)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Miravant Medical Technologies Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Miravant Medical Technologies Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten